Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.WT

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 72% CR at any point in time.

<< Previous

Bullboard Posts

Next >>

Comment by NotinKansason May 01, 2023 7:14am

132 Views

Post# 35422309

RE:RE:RE:RE:RE:72% CR at any point in time.

Sorry, I read you wrong, nothing too rosy in your numbers indeed. I'm also looking at a mid-thirties CR rate at 450 days ex. Phase Ib and ex. first 12 Phase II. And in addition to that, a 63% likelihood of someone remaining CR until 450 days if they achieved CR at 90 days (this based on all Phase II data so far). This percentage would probably also be higher if you remove the first 12, but since we don't know exactly which swimmers in the plot make up the first 12, that calculation is hard to complete.

Anyway, forward we move.

<< Previous

Bullboard Posts

Next >>

Sparta and Parametric join forces to advance autonomous medicine project